Edina Cenko/Redcliffe Cardiology and Erik Stroes/amsterdamumc.nl
Sep 13, 2026, 16:51
Edina Cenko: AZURE-HeFH Highlights the LDL-C Treatment Gap in HeFH
Edina Cenko, Past-Chairperson ESC Working Group on Coronary Pathophysiology and Microcirculation at European Society of Cardiology, shared on LinkedIn:
“Presented by Erik Stroes at ESC Congress 2026, baseline cohort data from the Phase 3 AZURE-HeFH trial evaluating the novel oral PCSK9 inhibitor laroprovstat vs placebo.
Lifelong cumulative exposure makes aggressive LDL-C lowering essential in HeFH—yet less than 25% hit guideline targets on conventional oral LLT.
- N is 472 genetically or clinically confirmed HeFH participants
- Approximately 21% with prior ASCVD
- 94% on statins (more than 80% high-intensity) and 73.1% on ezetimibe
- Mean baseline LDL-C: 2.95 mmol/L despite intensive combination background therapy
These findings underline the profound implementation gap in HeFH.
Looking forward to primary 12-week and 52-week safety or efficacy outcomes.”
Other posts featuring Edina Cenko on Hemostasis Today.
-
Sep 13, 2026, 16:51Axay Tomar: How Simulation-Based Education Shapes Safer Transfusion Practices
-
Sep 13, 2026, 16:49William Aird: Why Is LDH Elevated In Splenic Infarction?
-
Sep 13, 2026, 16:48David McIntosh: PPTA Calls for Action on the Global Shortage of Plasma-Derived Medicines
-
Sep 13, 2026, 16:45Shabnam Arsiwala: Did You Know Sickle Cell Disease Can Threaten Vision?
-
Sep 13, 2026, 16:43Foncha Joshua: Donate Blood, Save a Life, Be Someone’s Miracle
-
Sep 13, 2026, 16:40Natalia Schütz: Academic Exchange at the Uruguayan Congress of Hematology
-
Sep 13, 2026, 16:39Chokri Ben Lamine: Representing Saudi Arabia at SOHO26
-
Sep 13, 2026, 16:39Asmaa M. Gouda: A Memorable Learning Experience in Immunohematology and Transfusion Medicine
-
Sep 13, 2026, 16:33Why the Immune Response Matters in Hemophilia Treatment – WFH